CME credits: 0.25

Valid until: 14-03-2025

Claim your CME credit at https://reachmd.com/programs/cme/cracking-the-crs-code-in-myeloma-insights-from-a-comprehensive-case-review/17876/

Bispecific antibodies are the newest immunotherapies approved for heavily pretreated relapsed/refractory myeloma, and they are shown to double response rates. Are you ready to use them in your practice? Join Drs. Costello and Lonial as they explore a case study that demonstrates how to select patients, prepare them for treatment, and effectively manage treatment-related side effects.

=